Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
5e5 of anti-EGFRvIII CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human EGFRvIII Protein, His Tag (Cat. No. EGI-HA2H8) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).
5e5 of anti-EGFRvIII CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human EGFRvIII Protein, His Tag (Cat. No. EGI-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Immobilized Human EGFRvIII, His Tag (Cat. No. EGI-H52H4) at 1 μg/mL (100 μL/well) can bind Anti-EGFRvIII Antibody , Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).
The purity of Human EGFRvIII, Fc Tag (Cat. No. EGI-H5255) is more than 90% and the molecular weight of this protein is around 150-184 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| EGFRvIII-CAR | Phase 1 Clinical | Duke University Medical Center | Glioblastoma | Details | |
| EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) | LXF-821 | Phase 1 Clinical | University Of Pennsylvania, Novartis Pharma Ag | Glioblastoma | Details |
| hEGFRvIII-CD3 Bi-scFv | Duke University | Details | |||
| EGFRvIII Targeted Chimeric Antigen Receptor CAR-T Cell Therapy (Chembrain) | Chembrain Ltd | Details | |||
| Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) | CPGJ-602; 602; CPGJ602; CPGJ 602 | Phase 2 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Colorectal Neoplasms | Details |
| AMG-595 | AMG-595 | Amgen Inc | Details | ||
| GNC-039 | GNC-039 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis | Details |
| Anti-EGFRvIII-CAR | EGFRvIII CAR; Anti-EGFRvIII-CAR | Phase 2 Clinical | National Cancer Institute | Glioblastoma; Brain Neoplasms; Gliosarcoma; Glioma | Details |
| RO-7428731 | RO-7428731 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Glioblastoma | Details |
| Etevritamab | AMG-596 | Phase 1 Clinical | Amgen Inc | Glioblastoma | Details |
| EGFRvIII-CAR | Phase 1 Clinical | Duke University Medical Center | Glioblastoma | Details | |
| EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) | LXF-821 | Phase 1 Clinical | University Of Pennsylvania, Novartis Pharma Ag | Glioblastoma | Details |
| hEGFRvIII-CD3 Bi-scFv | Duke University | Details | |||
| EGFRvIII Targeted Chimeric Antigen Receptor CAR-T Cell Therapy (Chembrain) | Chembrain Ltd | Details | |||
| Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) | CPGJ-602; 602; CPGJ602; CPGJ 602 | Phase 2 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Colorectal Neoplasms | Details |
| AMG-595 | AMG-595 | Amgen Inc | Details | ||
| GNC-039 | GNC-039 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis | Details |
| Anti-EGFRvIII-CAR | EGFRvIII CAR; Anti-EGFRvIII-CAR | Phase 2 Clinical | National Cancer Institute | Glioblastoma; Brain Neoplasms; Gliosarcoma; Glioma | Details |
| RO-7428731 | RO-7428731 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Glioblastoma | Details |
| Etevritamab | AMG-596 | Phase 1 Clinical | Amgen Inc | Glioblastoma | Details |
This web search service is supported by Google Inc.
A-Z
